Calistoga Pharmaceuticals

Developing innovative oral medicines targeting selected isoforms of the PI3 kinase pathway to improve the health of patients with cancer and inflammatory diseases.

Launch date

2006

Employees

2-10 people

Market cap

Enterprise valuation

€341m (Public information from Feb 2011)

Seattle Washington (HQ)

http://calistogapharma.com

http://www.facebook.com/pages/Calistoga-Pharmaceuticals-Inc/113814801967208 https://www.linkedin.com/company/calistoga-pharmaceuticals

Date	Investors	Amount	Round
Mar 2007	Alta Partners Three Arch Partners Amgen Ventures Frazier Healthcare Partners	$21.0m	Series A
Jan 2008	Alta Partners Three Arch Partners Amgen Ventures Frazier Healthcare Partners	$5.2m	Series A
Mar 2009	N/A	$1.0m	Series A
May 2009	Alta Partners Three Arch Partners Amgen Ventures Frazier Healthcare Partners	$30.0m	Series B
Jun 2010	Latterell Venture Partners Alta Partners Three Arch Partners Amgen Ventures Frazier Healthcare Partners	$40.0m	Series C
Feb 2011	Gilead Sciences	$375m Valuation: $375m	Acquisition
Total Funding		€88.4m

Tech stackLearn more about the technologies and tools that this company uses.

Calistoga Pharmaceuticals

Calistoga Pharmaceuticals

Recent News about Calistoga Pharmaceuticals

Tech stack